Filgrastim - Center of Molecular ImmunologyAlternative Names: Filgrastim - CIMAB; IorLeukoCIM
Latest Information Update: 22 Sep 2016
At a glance
- Originator Center of Molecular Immunology
- Developer Center of Molecular Immunology; CIMAB
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
- Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 14 Jan 2016 Launched for Neutropenia in Cuba (SC) before January 2016 (CIMAB SA pipeline; January 2016)